ClinicalTrials.gg
RecruitingNCT03003572I GET DRYUpdated May 6, 2026

Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity

An observational study in Primary Sjögren's Syndrome, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

How we know

From the registry’s dates

  • Started Mar 2018; still recruiting 8 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
185
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.

Planned enrollment
8th of 18
185 · median 110
Started
2018
the only one that year
Observational
18 of 58
6 open now
Primary completion
2027-06
later than 10 of 24 live
Registered
11th of 58
by date
Lead sponsor
2 of 58
Centre Hospitalier Universitaire de Saint Etienne

Among the 58 studies in Sjogren's Syndrome with a site in France, this one is the 8th largest by planned enrollment of the 18 observational ones that give a count, is the only one that started in 2018, is one of 18 observational ones, reaches primary completion later than 10 of the 24 other live ones, and was the 11th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sjogren's Syndrome with a site in France, or all of them as a file.
02

Study summary

Primary Sjögren's syndrome (pSS) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life. Its evolution is chronic, with flares and relapses, and the need for reliable biomarkers to be carried out routinely is major in patients' follow-up. Because of the existence of autoreactive immunoglobulins E (IgE) in autoimmune diseases, the recently described role for anti-Ro/SSA antibodies in inducing interferon alpha (IFNα) signaling and the specific pharmacologic properties of IgE, anti-Ro/SSA IgE should be an interesting biomarker to determine pSS's activity. The aim of the study is to evaluate whether the proportion of anti-Ro/SSA IgE positive patients is higher in patients with active disease (i.e. Eular Sjögren Syndrome Disease Activity Index≥ 5). All consecutive patients with pSS (new or already known diagnosis) will be included, Anti-Ro/SSA IgE titers will be determined, the disease's features will be collected (including Eular Sjögren Syndrome Disease Activity Index/Eular Sjogren's Syndrome Patient Reported Index).

03

Conditions studied

  • Primary Sjögren's Syndrome

Keywords

  • Sjögren's syndrome
  • Immunoglobulin E
  • Anti-Ro/SSA
  • Autoimmune disease
  • Biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with primary Sjögren's syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary Sjögren's syndrome according to the American-European Consensus Criteria)
  • Informed and having signed the study consent form

Exclusion criteria

Exclusion Criteria:

  • Secondary Sjögren's syndrome
  • Other systemic disease (e.g. rheumatoid arthritis, AntiNeutrophil Antibodies (ANCA) -associated vasculitis, mixed connective tissue disease…)
  • Incapacity or refusal to sign the form
  • Incapacity or refusal to perform the follow-up examinations required by the study
  • Has received abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, Tumor Necrosis Factor (TNF) antagonists or interferon during the 6 months prior to the inclusion
  • Has any current signs or symptoms of active infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
185 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • patients with primary Sjögren's syndrome

    Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.

    Other: Blood samples

Interventions

  • OtherBlood samples

    Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).

06

What researchers measure

Primary outcomes

  1. Proportion of anti-Ro/SSA IgE positive patients

    Comparison of proportion of anti-Ro/SSA IgE positive patients between patients with active pSS and patient without active pSS anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Active pSS is defined by Eular Sjögren Syndrome Disease Activity Index (ESSDAI) ≥ 5

    Time frame: Day 1

Secondary outcomes

  1. Correlation between anti-Ro/SSA IgE titers and pSS's activity.

    pSS's activity is defined by Eular Sjögren Syndrome Disease Activity Index (ESSDAI). Anti-Ro/SSA IgE titers is measured by serial dilutions of the serum. Anti-Ro/SSA IgE titers is the last dilution whose absorbance (in optical density) is higher than positivity threshold.

    Time frame: Day 1

  2. Correlation between anti-Ro/SSA IgE positive patients and the symptomatology level

    Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). The symptomatology level is measured by the Score Eular Sjogren's Syndrome Patient Reported Index (ESSPRI). If ESSPRI≥5: symptomatology whose intensity felt by the patient is not acceptable. If ESSPRI\<5: symptomatology whose intensity felt by the patient is acceptable.

    Time frame: Day 1

  3. Correlation between anti-Ro/SSA IgE positive patients and onset of lymphoma

    Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). There is a medical monitoring every years by medical record and/or by phone know that a development of lymphoma.

    Time frame: 5 years

  4. Correlation between anti-Ro/SSA IgE positive patients and interferon alpha signature

    Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Interferon alpha signature level is measured by real-time Polymerase Chain Reaction (PCR). They calculate the average of delta cycle threshold in messenger ribonucleic acid (mRNA) of regulate gene by interferon alpha.

    Time frame: Day 1

  5. Comparison between anti-Ro/SSA IgE positive patients and clinical and biologic characteristics

    Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Composite outcome of clinical and biologic characteristics is describe below. Clinical characteristics: type of affected organs, lymphoma medical history, allergic disorders, scores Eular Sjögren Syndrome Disease Activity Index (ESSDAI), Eular Sjogren's Syndrome Patient Reported Index (ESSPRI) and analogue visual scale disease patient and doctor, saliva flow and Schirmer test. Biologic characteristics: anti-Ro/SSA IgE titers, rheumatoid factor titers and number of totals lymphocytes and T cluster of differentiation 4 (CD4) lymphocytes.

    Time frame: Day 1

  6. Comparison between anti-La/SSB IgE positive patients and clinical and biologic characteristics

    Anti-La/SSB IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Composite outcome of clinical and biologic characteristics is describe below. Clinical characteristics: type of affected organs, lymphoma medical history, allergic disorders, scores Eular Sjögren Syndrome Disease Activity Index (ESSDAI), Eular Sjogren's Syndrome Patient Reported Index (ESSPRI) and analogue visual scale disease patient and doctor, saliva flow and Schirmer test. Biologic characteristics: anti-La/SSB IgE titers, rheumatoid factor titers and number of totals lymphocytes and T CD4 lymphocytes.

    Time frame: Day 1

07

Study locations

5 of 8 sites recruiting
  • CH Pierre Oudot
    Bourgoin, 38300, France
    Not yet recruiting
    • Marielle ROUX, MD · Contact
    • Marielle ROUX, MD · Principal investigator
  • CHU Estaing - Clermont Ferrand
    Clermont-Ferrand, 63000, France
    Recruiting
    • Marc RUIVARD, MD PhD · Contact
    • Marc RUIVARD, MD PhD · Principal investigator
    • Virginie RIEU, MD · Sub investigator
    • Vincent GROBOST, MD · Sub investigator
  • CHU Grenoble Alpes
    Grenoble, 38700, France
    Recruiting
    • Laurence BOULLET, MD PhD · Contact
    • Laurence BOUILLET, MD PhD · Principal investigator
    • Françoise SARROT-REYNAULD, MD · Sub investigator
    • Alban DEROUX, MD · Sub investigator
    • Alexis BOCQUET, MD · Sub investigator
    • Aurélie MADELON, MD · Sub investigator
  • Hôpital de la Croix Rousse
    Lyon, 69317, France
    Recruiting
    • Pascal SEVE, MD · Contact
    • Pascal SEVE, MD · Principal investigator
    • Yvan JAMILLOUX, MD · Sub investigator
    • Mathieu GERFAUD-VALENTIN, MD · Sub investigator
    • Claire BERNARD, MD · Sub investigator
    • Mathilde FRANÇOIS, MD · Sub investigator
  • CH Lyon Sud
    Lyon, 69495, France
    Recruiting
    • Jean-Christophe LEGA, MD · Contact
    • Jean-Christophe LEGA, MD · Principal investigator
    • Quitterie REYNAUD, MD · Sub investigator
    • Isabelle DURIEU, MD · Sub investigator
    • Sabine MAINBOURG, MD · Sub investigator
  • Hôpital Edouard Herriot - CHU Lyon
    Lyon, France
    Not yet recruiting
    • Arnaud HOT, MD PhD · Contact
    • Arnaud HOT, MD PhD · Principal investigator
    • Cécile-Audrey DUREL, MD · Sub investigator
  • CHU Reims
    Reims, France
    Not yet recruiting
    • Amélie SERVATTAZ, MD PhD · Sub investigator
  • Chu Saint-Etienne
    Saint-Etienne, 42055, France
    Recruiting
    • Pascal CATHEBRAS, MD PhD · Contact
    • Pascal CATHEBRAS, MD PhD · Principal investigator
    • Isabelle GUICHARD, MD · Sub investigator
    • Jean-Baptiste GAULTIER, MD · Sub investigator
    • Anne-Emmanuelle DEPINCE-BERGER, MD · Sub investigator
    • Thierry THOMAS, MD PhD · Sub investigator
    • Hubert MAROTTE, MD PhD · Sub investigator
    • Héloïse MUNOZ-PONS, MD · Sub investigator
    • Martin KILLIAN, MD · Sub investigator
    • Béatrice PALLOT-PRADES, MD · Sub investigator
    • Karima BOUSSOUALIM, MD · Sub investigator
    • Mijola LAMBERT, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Jun 2027, 111 months after the start.

Of 40 observational studies under Sjogren's Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 21. This study's planned 111 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2016
First posted
Dec 28, 2016
StartActual
Mar 27, 2018
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03003572
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Mar 27, 2018
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 6, 2026

Study contacts

Pascal CATHEBRAS, MD PhD
Contact
pascal.cathebras@chu-st-etienne.fr
(0)477828342 ext. +33
Florence RANCON, CRA
Contact
florence.rancon@chu-st-etienne.fr
(0)477120284 ext. +33
Pascal CATHEBRAS, MD PhD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion